A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Amivantamab and Hyaluronidase-Lpuj (Human Recombinant) (Rybrevant Faspro)

Endoglycosidase class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2025-12-19
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Amivantamab and Hyaluronidase-Lpuj (Human Recombinant) used for?

Amivantamab and Hyaluronidase-Lpuj (Human Recombinant) is a Endoglycosidase medication tracked in Medicare Part D.

Is there a generic for Amivantamab and Hyaluronidase-Lpuj (Human Recombinant)?

No. Amivantamab and Hyaluronidase-Lpuj (Human Recombinant) is brand-only with no generic equivalents currently in market.

How much does my plan pay for Amivantamab and Hyaluronidase-Lpuj (Human Recombinant)?

NADAC pricing data not currently available for this drug.

Is Amivantamab and Hyaluronidase-Lpuj (Human Recombinant) on the FDA shortage list?

No. Amivantamab and Hyaluronidase-Lpuj (Human Recombinant) is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Endoglycosidase6 alternatives in D1
01
Hyaluronidase
Brand: AMPHADASE
$53.43Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Ocrelizumab and Hyaluronidase
Brand: Ocrevus Zunovo
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Pembrolizumab and Berahyaluronidase Alfa-Pmph
Brand: KEYTRUDA QLEX
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf
Brand: Phesgo
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Rituximab and Hyaluronidase
Brand: Rituxan Hycela
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
06
Trastuzumab and Hyaluronidase-Oysk
Brand: Herceptin Hylecta
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.